

To the FDA:

RE: DOCKET NO. 98N-1265

I send this letter as a consumer of healthcare services to register my concern and disapproval of the Memorandum of Understanding as published by the FDA on January 21, 1999.

In its present form, the MOU, as well as the Compounding Section 503A of the Modernization Act, severely restricts the rights of the physicians and patients to obtain healthcare products from the provider of their choice. It also infringes on the rights of compounding pharmacists to serve the public's medical needs. As a healthcare consumer, there should be no restrictions to the delivery of a compounded medication prescribed for me, regardless of where I may live or may travel. The MOU must be amended!

Signed:

Judy G. Solenberger

State of Residence:



Kansas

Comments:

I react much better to
my compounded estrogen than I do
to patented estrogens. At age 50 its
the difference of being able to take estrogen
or not. I have several conditions that benefit

98N-1265

C4694



DOCKETS MANAGEMENT BRANCH (HFA-305)
FOOD AND DRUG ADMINISTRATION
5630 FISHERS LN RM 1061
ROCKVILLE MD 20857-0003

